Skip to main content

Advertisement

Table 2 Asthma disease characteristics by cohort at baseline visit

From: Longitudinal stability of asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study

  Asthma severity cohort  
Cohorts* Mild Moderate Severe P-value ***
N (total/sputum) 52/32 55/38 51/40  
Age (years) 33.7 (13.1) 45.0 (11.6) 46.2 (12.1) <10−6
Pre-BD FEV1 (% predicted) 92.7 (14.3) 73.6 (10.4) 65.4 (12.7) < 10−6
Pre-BD FEV1/FVC ratio 0.77 (0.08) 0.66 (0.09) 0.61 (0.09) < 10−6
Post-BD FVC (% predicted) 105.0 (15.5) 96.4 (11.4) 94.0 (15.1) 0.0004
BDR (% change in FEV1) 8.5 (8.3) 15.2 (10.3) 18.3 (14.5) 0.0016
BDR (mL change in FEV1) 265.1 (231.7) 335.2 (234.3) 355.7 (270.6) 0.45
ACQ7 0.84 (0.69) 1.33 (0.71) 1.92 (1.01) < 10−6
AQLQ 5.86 (0.93) 5.68 (1.11) 5.09 (1.28) 0.0016
FENO (ppb) ** 32.9 (+64.2/−16.9) 29.1 (+61.0/−13.9) 28.8 (+64.7/−12.9) 0.59
Sputum eosinophils, % of WBC ** 1.12 (+5.38/−0.93) 3.12 (+13.62/−2.54) 2.70 (+12.27/−2.21) 0.033
Sputum lymphocytes, % of WBC 1.29 (1.42) 0.98 (1.19) 0.94 (1.25) 0.48
Sputum macrophages, % of WBC 50.20 (31.17) 32.10 (21.45) 43.04 (26.46) 0.019
Sputum neutrophils, % of WBC 43.88 (30.90) 56.99 (26.13) 48.10 (25.52) 0.13
  1. * Mean (standard deviation) reported by cohort, unless otherwise indicated
  2. ** Geometric mean (asymmetric standard deviation) reported by cohort
  3. *** p-value (ANOVA F-test for differences across asthma severity cohorts (based on log-transformed data when geometric means reported)